Zopapogene imadenovec · Papzimeos

Gene therapy / editing

Approvedregulatory verdict

Evidence outlook

Approved: Recurrent Respiratory Papillomatosis

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (1)
Recurrent Respiratory Papillomatosis
NCT07901738 · Precigen, Inc
2026-12-31 – 2033-01 · Recurrent Respiratory Papillomatosis (RRP), Juvenile-onset Recurrent Respiratory Papillomatosis, Papillomavirus Infections
What this study did
Phase 2 (1)
Recurrent Respiratory Papillomatosis
Phase 1/2 (1)
Recurrent Respiratory Papillomatosis
Phase 4 (1)
Recurrent Respiratory Papillomatosis
NCT06538480 · Precigen, Inc
2024-07-11 – 2028-12-02 · Recurrent Respiratory Papillomatosis, Papillomavirus Infection, Papillomaviridae
What this study did

Competitive landscape

This drug's own stage for Recurrent Respiratory Papillomatosis: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Zopapogene Imadenovec (Papzimeos): this drugApprovedGene therapy / editingHPV6/HPV11 antigens (immunotherapy)not yet gradedNo reviewed efficacy summary in this indication
INO-3107 (Voceryq)ApprovedGene therapy / editingHPV-6 and HPV-11 antigensWeak signalFeatured results are safety only in this race

Upcoming events

(3 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Papzimeos (Zopapogene imadenovec) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
December 2027 (1)
Phase 4Recurrent Respiratory PapillomatosisRecruiting
Est. primary completion 2027-12-02 · NCT06538480 · CT.gov ↗
What to watch
2029 (2)
January 2029 (1)
Phase 3Recurrent Respiratory PapillomatosisNot yet recruiting
Est. primary completion 2029-01 · NCT07901738 · CT.gov ↗
What to watch
July 2029 (1)
Phase 2Recurrent Respiratory PapillomatosisNot yet recruiting
Est. primary completion 2029-07-01 · NCT07756840 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(5)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

27 August 2025FDA action datePDUFA target action date set for August 27, 2025
US, FDA · Source ↗
15 August 2025ApprovalFDA full approval of PAPZIMEOS for adult RRP
US, FDA · Source ↗
25 February 2025Filing acceptedFDA accepts BLA for PRGN-2012
US, FDA · Source ↗
25 February 2025Priority reviewFDA grants priority review to PRGN-2012 BLA
US, FDA · Source ↗
December 2024Filing submittedRolling BLA submission completed
US, FDA · Source ↗